Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 196

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 196
---
, cash equivalents and restricted cash was $57 for the year ended December 31, 2024 compared to $(50) for the year ended
December 31, 2023. The increase of $107 was primarily attributable to changes in the exchange rate between the U. S. Dollar and the Israeli
NIS.

Funding Requirements

We expect our expenses to
increase in connection with our ongoing activities, particularly as we continue the research and development for, initiate later stage
clinical trials for, and seek further marketing approvals for, our Alpha DaRT technology and other potential future product candidates.
In addition, if we obtain further marketing approvals for our Alpha DaRT technology and other potential future product candidates, we
expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore,
we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms,
we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

We expect that our existing
cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least two years. We
have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently
expect. Our future capital requirements will depend on many factors, including:

  the costs of conducting future                 

  the costs of manufacturing additional                                                                                                 

  the costs of scaling up our                                                                                                            

  the scope, progress, results                                                                                                           
  and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may  
  develop, if any;                                                                                                                       
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  the costs, timing and outcome                                                                     

  our ability to establish and                            

  the achievement of milestones                                                                                             

  the costs and timing of future                                                                                                           

  the amount of revenue, if any,                                                                                                        

  the costs of preparing, filing                                                                                                         

  our headcount growth and associated                                                          

  the costs of operating as a  

Identifying potential product
candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years
to complete, and we may never generate the necessary data or results required to obtain further marketing